|
|
Post by jeremg on Nov 19, 2015 17:04:14 GMT -5
I think the way you are interpreting "not yet" is a little generous, Matt has been known to mislead in his statements as @kastanes emails have shown two or three times in the past. I'm interpreting that "not yet" the way it was likely intended "no they haven't, but i'll go ahead and add some optimistic fodder for the shareholders to feed off of [not YET]". I have never interpreted Matt's email replies as misleading or ingenious. Matt was stating his opinion, confined within corporate legal parameters. To do otherwise would be an invitation for lawsuits. That was simply my interpretation of what you posted, although I think you are fooling yourself if you have come to a different conclusion on Matt's intent with those answers to your inquiries. I found Matt's responses to be purposefully vague and misleading, I'm sure he knew what you were asking and your intent in asking, yet he still chose to give an answer that misled you into believing the issue was put to rest. I would caution you to practice a little more concern when interpreting Matt's responses as "unequivocal", you may mislead others into believing what you have posted and hinder further debate (which you actually actively tried to do in this instance). Honestly, I can't understand your blind defense of management's actions. On Nov 2, 2015, at 8:33 AM, Pfeffer,Matt wrote: "No. Dual listing just means the existing shares can trade on more than one exchange."Not sure why people are still confused? Matt gave a definitive answer, I am sure he will discuss this during the earnings call." Read more: mnkd.proboards.com/user/1363/recent#ixzz3rybpB9Gp"Matt has given an unequivocally answer regarding potential dilution by listing on two exchanges. Why is this debate continuing?
Please lock this thread."
Read more: mnkd.proboards.com/user/1363/recent#ixzz3rybiWE1S |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 19, 2015 18:14:08 GMT -5
Please enlighten me how Matt's email replies or my comments are false. His replies stated the obvious, which some people are unable or unwilling to accept. Yes, I mentioned locking the thread because there is no point debating a future event because of the many unknowns. I don't care to speculate, I try to understand the situation as best as possible, then act. If that is your definition of hinder, best of luck. You are going to need it  |
|
|
|
Post by afrizzle on Nov 19, 2015 19:12:30 GMT -5
I've been trying to find an iota of sympathy for Mr Short but seem to be all out
|
|
|
|
Post by jeremg on Nov 19, 2015 19:18:12 GMT -5
Please enlighten me how Matt's email replies or my comments are false. His replies stated the obvious, which some people are unable or unwilling to accept. Yes, I mentioned locking the thread because there is no point debating a future event because of the many unknowns. I don't care to speculate, I try to understand the situation as best as possible, then act. If that is your definition of hinder, best of luck. You are going to need it I think trying to lock threads that you disagree with based on faulty interpretation of [mis]information is a pretty solid attempt at hindering honest discussion. I have seen you say things with certainty time and time again only to be proven wrong after abrasively defending your position ("you need to have your ears checked, Matt said $10mil per quarter"). I'm not sure why I am going to need luck because I disagree with your questonsble methods, but best of luck to you as well. . |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 19, 2015 22:24:18 GMT -5
If you took the time to read further, I acknowledged I was wrong with respect to $10 million per quarter. Of course, you select the comment that fits your twisted hypothesis. This reminds me of trolls on SA that distort positive facts into negatives. Better luck with that joke of a website SA.
|
|
|
|
Post by mnholdem on Nov 20, 2015 8:39:54 GMT -5
Biotech's Bad Boy Martin Shkreli Named CEO of KaloBios (KBIO)
11/20/2015 5:45:36 AM
KaloBios Pharmaceuticals, Inc. Appoints Martin Shkreli CEO and Announces New Financing
Martin Shkreli, David Moradi, Tony Chase and Marek Biestek to join the Board of Directors
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), today announced that an investor group led by Martin Shkreli, the Founder and Chief Executive Officer of Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares. KaloBios also announced the appointment of Martin Shkreli to the position of Chief Executive Officer and his election as Chairman of the Board. In his new role, Mr. Shkreli will work with the company's senior management team to ensure the Company's continued operations. KaloBios further announced that David Moradi, Tony Chase and Marek Biestek have been elected to the Board of Directors. In connection with these developments, the former directors have resigned, effective immediately.
Source: www.biospace.com/News/biotechs-bad-boy-martin-shkreli-named-ceo-of/400449/source=TopBreaking
|
|
|
|
Post by babaoriley on Nov 28, 2015 10:41:04 GMT -5
Saw this on the newswire recently, enough to make the turkey turn over in one's gut! He'll need the money to pay his lawyers.
KaloBios soared 29% after the self-proclaimed biotech specialist in cancer-fighting monoclonal antibodies found its shares involved in a classic short squeeze. The company has seen its stock soar from just $1 per share a few weeks ago, and on Nov. 13, the company said that it would wind down its operations and liquidate its assets. Yet then, infamous Turing Pharmaceuticals CEO Martin Shkreli bought up a majority stake in the company and became KaloBios' CEO last week, sending the stock as high as $40 per share. Today's move came after Shkreli said that he would no longer make his shares available for short-sellers to bet against the stock, and that resulted in a stampede among those who were short the stock to find shares to cover their positions. Many are calling for SEC action in response to wild trading in what was a penny stock until this month, but investors should expect continued swings as bulls and bears fight it out.
|
|
|
|
Post by mnholdem on Nov 30, 2015 12:14:17 GMT -5
www.biospace.com/News/shkrelis-turing-pharma-rolls-out-a-50-price-cut/400926/source=TopBreaking
Shkreli's Turing Pharma Rolls Out a 50% Price Cut for Daraprim
11/25/2015 5:49:34 AM
By Mark Terry and Alex Keown, BioSpace.com Breaking News Staff
New York and Zug, Switzerland-based Turing Pharmaceuticals LLC announced yesterday a 50 percent cut in its prices for toxoplasmosis drug Daraprim.
Turing and its controversial chief executive officer Martin Shkreli became the focus of a national discussion of drug pricing in August after it acquired Daraprim from IMPAX Laboratories, Inc. (IPKL) for $55 million. When acquired, the drug was priced for $13.50 per tablet. Turing increased the price to $750 per pill, an increase of about 5,000 percent.
The drug typically used to treat toxoplasmosis, a parasitic disease, in patients with compromised immune systems, such as cancer and HIV patients, as well as pregnant women. The drug has been on the market for over 60 years.
In addition to the 50 percent price drop, the company will supply the drug in smaller bottles of 30 tablets, suggesting that will make it easier to stock the drug. It will also provide free samples of the drug to physicians so they can easily start therapy in emergency situations. All of these are to go into effect in early 2016.
A 50 percent cut to about $375 per pill isn’t likely to appease critics of the company or Shkreli. The drug is available in Europe for under $1 per pill.
|
|
|
|
Post by dreamboatcruise on Nov 30, 2015 14:29:18 GMT -5
mnholdem... what a generous crook he is (eyes rolling).
|
|
|
|
Post by mnholdem on Nov 30, 2015 14:57:17 GMT -5
|
|
|
|
Post by liane on Nov 30, 2015 16:43:23 GMT -5
I just feel bad for the patients that need this drug.
|
|
|
|
Post by stevil on Nov 30, 2015 17:59:14 GMT -5
|
|
|
|
Post by mssciguy on Nov 30, 2015 18:11:39 GMT -5
I just feel bad for the patients that need this drug. I saw an article about a compounding firm that would be able to offer the equivalent for a buck a pill or so, it's on the way. Ironically toxoplasma is transmitted by cat feces (as I am sure you know), cat lovers should be aware, wear gloves when handling that, keep kids away. |
|
|
|
Post by liane on Nov 30, 2015 18:16:17 GMT -5
I just feel bad for the patients that need this drug. I saw an article about a compounding firm that would be able to offer the equivalent for a buck a pill or so, it's on the way. Ironically toxoplasma is transmitted by cat feces (as I am sure you know), cat lovers should be aware, wear gloves when handling that, keep kids away. It's only a problem if you are immune-compromised or pregnant. |
|
|
|
Post by mnholdem on Dec 1, 2015 8:06:34 GMT -5
For those of you who have never read about how Martin Shkreli interfered with the FDA process for Afrezza, here is a link to one of the more detailed reports about what happened:
Link: afresa.blogspot.com/2012/01/mannkinds-afrezza-was-to-be-approved.html
Excerpt:
"Now the second part of this scandal. It involves Martin Shkreli, chief investment officer for New York based hedge fund, MSMB Capital Management, LLC. MSMB is notorious for short selling stocks and then creating questionable issues and making negative public comments and projections to drive down the stock price of the companies. In some cases, such as MannKind, he went further for self gain. CREW, the Citizens for Responsibility and Ethics in Washington has requested that the Security and Exchange Commission open an investigation of Martin Shkreli who appears to be illegally manipulating the market prices of stocks in the biotechnology and pharmaceutical industries. CREW claims Martin Shkreli has attempted to insert himself into the FDA approval process of at least 4 pending drugs in which he held a short position by contacting several FDA officials and working behind the scenes to affect the outcome of the FDA regulatory process. His claims to the FDA, arguably were biased and possibly fraudulent." |
|
